Literature DB >> 31005133

Antimicrobial Prophylaxis and Preemptive Approaches for the Prevention of Infections in the Stem Cell Transplant Recipient, with Analogies to the Hematologic Malignancy Patient.

Dionysios Neofytos1.   

Abstract

Infectious complications represent one of the most common causes of morbidity and mortality in allogeneic hematopoietic cell transplant (HCT) recipients. Prophylactic and preemptive treatment strategies against bacterial, fungal, viral, and parasitic pathogens are routinely implemented during high-risk post-HCT periods at most transplant centers. The basic concepts and review of current guidelines of antibiotic prophylaxis and empirical/preemptive antibiotic treatment in allogeneic HCT recipients are reviewed in this article.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibiotic prophylaxis; Antibiotics; Empirical treatment; Hematopoietic cell transplantation; Infectious complications; Neutropenia; Preemptive treatment

Year:  2019        PMID: 31005133     DOI: 10.1016/j.idc.2019.02.002

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  2 in total

1.  Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress?

Authors:  Romain Samuel Roth; Stavroula Masouridi-Levrat; Yves Chalandon; Anne-Claire Mamez; Federica Giannotti; Arnaud Riat; Adrien Fischer; Antoine Poncet; Emmanouil Glampedakis; Christian Van Delden; Laurent Kaiser; Dionysios Neofytos
Journal:  Open Forum Infect Dis       Date:  2021-11-29       Impact factor: 3.835

2.  Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.

Authors:  Alessandro Busca; Natascia Cinatti; Jessica Gill; Roberto Passera; Chiara Maria Dellacasa; Luisa Giaccone; Irene Dogliotti; Sara Manetta; Silvia Corcione; Francesco Giuseppe De Rosa
Journal:  Front Cell Infect Microbiol       Date:  2022-01-07       Impact factor: 5.293

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.